Healthcare Industry News: deep brain stimulation
News Release - March 15, 2016
Nuviant Medical Names Brian Blischak Chief Commercial OfficerKey Hire positions Nuviant for accelerated growth
DALLAS, March 15, 2016 /PRNewswire-iReach/ -- Nuviant Medical, Inc. ("Nuviant" or "the Company"), a medical device development and manufacturing company with proprietary closed-loop neuromodulation systems, announced today that Brian Blischak has joined the Company as Chief Commercial Officer (CCO). Mr. Blischak has over 20 years of experience in the medical device field and 16 years of experience in neuromodulation serving in senior commercial operations and executive roles for ImThera Medical and St. Jude Medical.
"Nuviant's innovative technology platform and rapid clinical development programs have enabled us to attract top talent," said Nuviant Chief Executive Officer Will Rosellini. "Brian brings with him invaluable experience in leading global commercialization strategies and operations, specifically for deep brain stimulation therapies."
Mr. Blischak joins from ImThera Medical, Inc., developer of an implantable neurostimulation system for sleep apnea, where he served for four years as Senior Vice President of Sales and Marketing. Prior to that, Mr. Blischak spent twelve years in the St. Jude Medical Neuromodulation Division (SJM), where he led the commercialization and launch of two major deep brain stimulation (DBS) product families consisting of over 20 products in more than 15 countries, including the patient recruitment efforts for two pivotal Investigational Device Exemption (IDE) studies for Parkinson's disease and essential tremor and two IDE feasibility studies for major depressive disorder. Mr. Blischak has a Bachelor of Science in Engineering Physics degree from the University of Saskatchewan, and a Master of Science in Biomedical Engineering and MBA degrees from The University of Texas at Austin. He is an inventor on nine issued US patents for neuromodulation devices.
"Nuviant's team is to be commended for developing and obtaining the CE Mark for the world's first rechargeable DBS system with both stimulating and sensing capabilities," said newly-appointed Nuviant CCO Brian Blischak. "I look forward to introducing this exciting new technology. Clinicians have waited a long time for a device like this."
About Nuviant Medical, Inc.
Nuviant Medical is a medical device company that has developed an innovative, closed-loop neuromodulation platform for the treatment of chronic neurological diseases. The Synapse™ system is currently the only system that can deliver up to 32 channels of stimulation while simultaneously recording neural signals, opening new possibilities for closed-loop neuromodulation therapies. The Synapse™ system previously received a CE Mark for adjunctive alleviation therapy of movement disorder symptoms and is being further developed for commercialization in Europe and the US. For more information on Nuviant Medical, please visit our website at www.nuviantmedical.com.
Forward-Looking Statements: This news release contains forward-looking statements which may be identified by their use of words like "plans," "expects," "will," "believes," "intends," "estimates," "anticipates" or other words of similar meaning. All statements that address expectations or projections about the future, including statements about the company's growth strategy, product development, regulatory approval, market position, anticipated benefits of acquisitions, timing of anticipated benefits from restructuring actions, outcome of contingencies, such as litigation and environmental matters, expenditures and financial results, are forward-looking statements. Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company's control. Some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements are: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; significant litigation and environmental matters; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; security threats, such as acts of sabotage, terrorism or war, weather events and natural disasters; ability to protect and enforce the company's intellectual property rights; successful integration of acquired businesses and separation of under-performing or non-strategic assets or businesses. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.
Source: Nuviant Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.